Search

Qingwei Deng

from Lexington, MA
Age ~56
Get Report
Connected to:
Aja B Deng, 52Alvin Deng, 34Anderia D Deng, 52Andrea W Deng, 30Bei Deng, 61Bobby Deng, 34Charles DengCindy X Deng, 60Clarence Deng, 30Dana Deng, 39

Qingwei Deng Phones & Addresses

  • 111 Burlington St, Lexington, MA 02420
  • Waltham, MA
  • Roxbury, MA
  • Watertown, MA
  • Brookline, MA
  • 132 Clocktower Dr #110, Waltham, MA 02452

Work

Company: Shire Aug 2007 Position: Scientist

Education

Degree: Masters School / High School: Mcgill University 2002 to 2004 Specialities: Neuroscience

Skills

Molecular Biology • Pharmacodynamic Biomarker Assay Developm... • Animal Work and Histology

Languages

English • Mandarin

Industries

Pharmaceuticals

Resumes

Resumes

Qingwei Deng Photo 1

Analytical Development Lead

View page
Location:
Lexington, MA
Industry:
Pharmaceuticals
Work:
Shire
Scientist
Immunogen, Inc. May 2006 - Jul 2007
Senior Research Associate
Dana-Farber Cancer Institute May 2005 - Apr 2006
Research Associate and Fellow
Mcgill University Jun 2002 - Mar 2005
Research Assistant
Medical College of Shihezi University Sep 1991 - Aug 1996
Research Scientist
Education:
Mcgill University 2002 - 2004
Masters, Neuroscience West China University of Medical Science 1996 - 1999
Master of Science, Masters Shihezi University 1991 - 1996
Bachelors, Medicine
Skills:
Molecular Biology
Pharmacodynamic Biomarker Assay Development
Animal Work and Histology
Languages:
English
Mandarin

Publications

Us Patents

Treatment Of Multiple Myeloma

View page
US Patent:
20100286090, Nov 11, 2010
Filed:
Nov 14, 2006
Appl. No.:
12/084657
Inventors:
Constantine S Mitsiades - Boston MA, US
Qingwei Deng - Watertown MA, US
Nicholas S. Mitsiades - West Roxbury MA, US
Kenneth C. Anderson - Wellesley MA, US
Joseph Negri - E. Falmouth MA, US
International Classification:
A61K 31/69
A61K 31/573
A61K 31/506
A61P 35/00
US Classification:
514 64, 514171, 51425219
Abstract:
Methods for treating multiple myeloma comprising administering a therapeutically effective amount of dasatinib to a patient in need of treatment thereof. Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib. The patient may be refractory to prior treatment with an anti-neoplastic agent other than dasatinib.
Control profile
Qingwei Deng from Lexington, MA, age ~56 Get Report